Methods of treating inflammation using IL-17 antagonists

Abstract

Aspects of the present invention provide methods for treating diseases associated with IL-17 mediated inflammatory or immunoregulatory reactions.

1 . A method of treating an individual afflicted with a disease associated with an IL-17-mediated inflammatory reaction, comprising administering to the individual having a disease associated with an IL-17-mediated inflammatory reaction an effective amount of an IL-17 antagonist. 
     
     
         2 . The method of  claim 1 , wherein the IL-17 antagonist is selected from the group consisting of (a) a soluble IL-17 receptor; (b) an antagonistic antibody that specifically binds IL-17; (c) an antagonistic antibody that specifically binds IL-17 receptor; or (d) combinations thereof. 
     
     
         3 . A method of treating rheumatoid arthritis in an individual in need thereof, comprising administering to the individual having rheumatoid arthritis an effective amount of an IL-17 antagonist. 
     
     
         4 . The method of  claim 3 , wherein the IL-17 antagonist is selected from the group consisting of (a) a soluble IL-17 receptor; (b) an antagonistic antibody that specifically binds IL-17; (c) an antagonistic antibody that specifically binds IL-17 receptor; or (d) combinations thereof. 
     
     
         5 . The method of  claim 2 , wherein the antagonistic antibody that specifically binds IL-17 is a monoclonal antibody. 
     
     
         6 . The method of  claim 4 , wherein the antagonistic antibody that specifically binds IL-17 is a monoclonal antibody. 
     
     
         7 . The method according to  claim 1 , further comprising administering, one or more therapeutics selected from the group consisting of a TNF antagonist and an IL-1 antagonist. 
     
     
         8 . The method of  claim 7 , wherein the IL-1 antagonist is selected from the group consisting of soluble IL-1 receptor type II, IL-1 R type I antibody, IL-1 receptor antagonist, and fusion protein comprising soluble IL-1 receptor type I, and soluble IL-1 receptor accessory protein. 
     
     
         9 . The method of  claim 7 , wherein the TNF antagonist is selected from the group consisting of TNF antibodies, soluble TNF receptor p75, and soluble TNF receptor p55.